StockNews.AI
ENSC
StockNews.AI
162 days

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

1. Ensysce secures partnership for next-gen opioid analgesics. 2. Positive interim results enhance market potential for PF614 and PF614-MPAR.

Earnings
-4.76%Current Return
VS
-0.84%S&P 500
$4.8303/10 04:19 PM EDTEvent Start
$4.603/11 10:57 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

The successful partnership and positive trial results indicate potential revenue growth and market expansion, similar to historical pharmaceutical successes post-approval.

How important is it?

The article discusses developments that are critical for ENSC's growth, particularly in a market seeking alternatives to opioids, thereby impacting investor sentiment and potential stock performance.

Why Long Term?

Partnerships and product launches typically contribute to sustained revenue growth over time, taking several quarters to fully realize market potential, akin to biotech firms like NVS and ABBV following new product introductions.

Related Companies

NVSABBVPTLA
Secures Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR Groundbreaking Trial on PF614-MPAR Generates Positive Interim Results SAN DIEGO, CA / ACCESS Newswire / March 10, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today reported financial and operational results for the fourth quarter and full year ended December 31, 2024. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "Our team continued to make significant strides in the fourth quarter to deliver what we believe are the ‘Next Generation' opioid analgesics with both abuse and overdose protection.

Related News